EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer

Xiaolin Zhu, Chien-Kuang C Ding, Rahul R Aggarwal

Current Oncology Reports · 2025

DOI: 10.1007/s11912-025-01643-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology Reports, 2025. Verfasst von Xiaolin Zhu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Molecular Targeted Therapy, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 114 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE OF REVIEW: Treatment-emergent neuroendocrine prostate cancer (NEPC) is aggressive and lethal. As androgen receptor signaling inhibitors (ARSIs) are increasingly used in earlier disease settings, treatment-emergent NEPC becomes more prevalent, and effective therapies are urgently needed. The purpose of this review was to summarize recent progress on emerging therapeutic targets of NEPC. RECENT FINDINGS: A multitude of therapeutic targets have emerged in NEPC over recent years. These targets may represent drivers of treatment-emergent lineage plasticity or simply be overexpressed on the surface of NEPC cells. Multiple modalities have been employed to drug these targets, with promising preclinical and clinical results. Treatment-emergent NEPC represents a distinct and clinically significant subset of castration-resistant prostate cancer (CRPC). Emerging therapeutic approaches have demonstrated encouraging efficacy and safety profiles, offering the potential to improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Targeted TherapyProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsCarcinoma, NeuroendocrineNeuroendocrine TumorsHumansMaleAndrogen Receptor AntagonistsReceptors, Androgen

Stichwörter der Autor:innen

Castration-resistant prostate cancer (CRPC)Cell surface markersNeuroendocrine prostate cancer (NEPC)Treatment-emergent lineage plasticity

Substanzen

Androgen Receptor AntagonistsReceptors, Androgen

Autor:innen und Institutionen

  • Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Department of Anatomic Pathology, University of California San Francisco, San Francisco, CA, USA.
  • Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. rahul.aggarwal@ucsf.edu.
  • Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA. rahul.aggarwal@ucsf.edu.

Zitieren

APA

Zhu, X., Ding, C. C., & Aggarwal, R. R. (2025). Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer. Current Oncology Reports. https://doi.org/10.1007/s11912-025-01643-9

Vancouver

Zhu X, Ding CC, Aggarwal RR. Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer. Current Oncology Reports. 2025. doi:10.1007/s11912-025-01643-9

BibTeX
@article{Zhu2025,
  author = {Zhu, Xiaolin and Ding, Chien-Kuang C and Aggarwal, Rahul R},
  title = {Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer},
  journal = {Current Oncology Reports},
  year = {2025},
  doi = {10.1007/s11912-025-01643-9}
}
Kostenlos starten →